Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Thoratec Corporation (NasdaqNM:THOR)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials
Recent Events
Aug 31Price hit new 52-week high ($20.20)
Location
6035 Stoneridge Drive
Pleasanton, CA 94588
Phone: (925) 847-8600
Fax: (925) 847-8574
Email: chess@thoratec.com
Employees (last reported count): 700
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Medical Equipment & Supplies
Company Websites
 ·Home Page
 ·Employment
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 55%
·Over the last 6 months:
 · 2 insider buys; 1.22M shares (3.7% of insider shares)
 · 7 insider sells; 3.75M shares
  (11.4% of insider shares)
·Institutional: 24% (54% of float)
(151 institutions)
·Net Inst. Buying: 1.55M shares (+10.44%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Thoratec Corporation develops, manufactures and markets proprietary medical devices used for circulatory support, vascular graft, blood coagulation and skin incision applications. The Company markets the Thoratec Ventricular Assist Device System (Thoratec VAD System) and the HeartMate Left Ventricular Assist System (the HeartMate LVAS) for use as a bridge to heart transplant. Additionally, the Thoratec VAD System is marketed for use in the recovery of the heart after open-heart surgery, and the HeartMate LVAS is marketed internationally as an alternative to medical therapy. The Company has also developed small diameter vascular grafts for use in hemodialysis access and coronary artery bypass surgery. All of these products that come into contact with human tissue or blood incorporate Thoralon, a proprietary biomaterial that provides strength and flexibility to its products, with surface properties designed to minimize patient blood clotting and inflammatory response.
More from Market Guide: Expanded Business Description

Financial Summary
Thoratec is engaged in the research, development, manufacturing and marketing of medical devices for circulatory support, vascular graft, blood coagulation and skin incision applications. For the six months ended 6/30/01, revenues rose 17% to $49.7 million. Net loss before extraordinary item totaled $85.3 million vs. an income of $4.2 million. Revenues reflect the merger. Net loss reflects $76.9 million in acquired in-process R&D expenses and $6.8 million in goodwill amortization.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

J. Donald Hill, 64
Chairman
--  --  
D. Keith Grossman, 40
Pres, CEO, Director
$470K--  
M. Wayne Bolyston, 43
CFO, Sr. VP
--  --  
Thomas Burnett, Jr., 37
COO, Sr. VP
336K$158K
Jeffrey Mack, 38
VP-Fin., Controller
--  --  
Dollar amounts are as of 30-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:THORAs of 31-Aug-2001
Price and Volume
52-Week Low
on 22-Mar-2001
$6.375
Recent Price$20.02 
52-Week High
on 31-Aug-2001
$20.20 
Daily Volume (3-month avg)547.6K
Daily Volume (10-day avg)783.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
26-Week Change+110.7%
26-Week Change
relative to S&P500
+129.4%
Share-Related Items
Market Capitalization$1.10B
Shares Outstanding55.1M
Float24.8M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$6.58 
Earnings (ttm)-$1.88 
Earnings (mrq)-$0.06 
Sales (ttm)$1.75 
Cash (mrq)$1.49 
Valuation Ratios
Price/Book (mrq)3.04 
Price/EarningsN/A 
Price/Sales (ttm)11.46 
Income Statements
Sales (ttm)$90.9M
EBITDA (ttm)-$79.4M
Income available to common (ttm)-$82.2M
Profitability
Profit Margin (ttm)-90.4%
Operating Margin (ttm)-94.9%
Fiscal Year
Fiscal Year EndsDec 30
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-20.33%
Return on Equity (ttm)-29.68%
Financial Strength
Current Ratio (mrq)6.75 
Debt/Equity (mrq)0.15 
Total Cash (mrq)$81.2M
Short Interest
As of 8-Aug-2001
Shares Short678.0K
Percent of Float2.7%
Shares Short
(Prior Month)
649.0K
Short Ratio1.27 
Daily Volume533.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   B = billions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.